G65152-1-5C was used to stain Resting PBMC and analyzed with 10x Genomics Gene Expression Flex with Feature Barcodes and Multiplexing kit with Fix-Stain protocol.

G65152-1-5C was used to stain PBMC under 4hr LPS + TI treatment and analyzed with 10x Genomics Gene Expression Flex with Feature Barcodes and Multiplexing kit with Fix-Stain protocol.

G65152-1-5C was used to stain Resting PBMC and analyzed with 10x Genomics Gene Expression Flex with Feature Barcodes and Multiplexing kit with Stain-Fix protocol.

G65152-1-5C was used to stain PBMC under 4hr LPS + TI treatment and analyzed with 10x Genomics Gene Expression Flex with Feature Barcodes and Multiplexing kit with Stain-Fix protocol.

Jurkat cells were subjected to SDS PAGE followed by western blot with 17227-1-AP (CD5 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 17227-1-AP (CD5 antibody) at dilution of 1:800 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 17227-1-AP (CD5 antibody) at dilution of 1:800 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

Immunofluorescent analysis of (4% PFA) fixed human tonsillitis tissue using CD5 antibody (17227-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Immunofluorescent analysis of (4% PFA) fixed human tonsillitis tissue using CD5 antibody (17227-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

IP Result of anti-CD5 (IP:17227-1-AP, 4ug; Detection:17227-1-AP 1:500) with mouse liver tissue lysate 6800ug.

1x10^6 human PBMCs were surface stained with 0.1 ug Anti-Human CD5 Mouse Recombinant Antibody (65530-1-PBS, Clone:L17F12) or Mouse IgG1 Isotype Control, and CoraLite®647-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L) at dilution 1:1000. Cells were then stained with CL488-conjugated Anti-Human CD19. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.1 ug Anti-Human CD5 Mouse Recombinant Antibody (65530-1-PBS, Clone:L17F12) or Mouse IgG1 Isotype Control, and CoraLite®647-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L) at dilution 1:1000. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 Rabbit Recombinant Antibody (65513-1-RR, Clone:UCHT2) or Rabbit IgG control PolyAb, and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7) at dilution 1:1000. Cells were then stained with CL488-conjugated Anti-Human CD19. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 Rabbit Recombinant Antibody (65513-1-RR, Clone:UCHT2) or Rabbit IgG control PolyAb, and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7) at dilution 1:1000. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 Rabbit Recombinant Antibody (65513-1-PBS, Clone:UCHT2) or Rabbit IgG control PolyAb, and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7) at dilution 1:1000. Cells were then stained with CL488-conjugated Anti-Human CD19. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 Rabbit Recombinant Antibody (65513-1-PBS, Clone:UCHT2) or Rabbit IgG control PolyAb, and CoraLite®647-conjugated AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (SA00014-7) at dilution 1:1000. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 (65200-1-Ig, Clone:L17F12) with CoraLite®594-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 or unstained. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 (65200-1-Ig, Clone:L17F12) with CoraLite®594-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 or unstained. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.1 ug Anti-Human CD5 Mouse Recombinant Antibody (65530-1-MR, Clone:L17F12) or Mouse IgG1 Isotype Control, and CoraLite®647-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L) at dilution 1:1000. Cells were then stained with CL488-conjugated Anti-Human CD19. Cells were not fixed. Lymphocytes were gated.

1x10^6 human PBMCs were surface stained with 0.1 ug Anti-Human CD5 Mouse Recombinant Antibody (65530-1-MR, Clone:L17F12) or Mouse IgG1 Isotype Control, and CoraLite®647-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L) at dilution 1:1000. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 (65152-1-Ig, Clone:UCHT2) and CoraLite®594-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 or unstained. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD5 (65152-1-Ig, Clone:UCHT2) and CoraLite®594-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 or unstained. Cells were not fixed. Lymphocytes were gated.